- EMEA Innovative Medicine
- Our innovation
- Focus areas
- Immunology
- Psoriasis
- Freedom from disease in psoriasis
Freedom from disease in psoriasis

Why do we need to define freedom from disease in psoriasis?
Collapse Why do we need to ensure patients are involved in every step of defining what freedom from disease in psoriasis is? Like many other conditions, people living with psoriasis and the doctors and nurses involved in their care can have different ideas about what successful treatment looks like. A doctor might look and see a reduction in dry and flaky skin, but a patient may still feel a persistent itch. The patient voice is therefore key to any definition about freedom from psoriasis.
In a recent study, a large group of patients, doctors and nurses helped build a consensus about what freedom from disease looks like in psoriasis.[3] They identified five core domains that need to be addressed for freedom from disease to be achieved:
- Quality of life and well-being
- Treatment
- Healthcare team support
- Psychosocial elements
- Management of clinical symptoms
These results will help foster better communication between doctors, nurses and their patients and lead to better understanding and improvements in the care of psoriasis.
Why is this important to people with psoriasis?
Needs
Voice
Treatment
Clinical tools
Learn more about freedom from disease in psoriasis
You are now leaving J&J Innovative Medicine EMEA
We inform you that the privacy policy at the remote site can be different from J&J Innovative Medicine EMEA. Click continue to proceed.
Patient organisations associated with this initiative
Asociația Pacienților cu Afecțiuni Autoimune (APAA), Romania
You are now leaving J&J Innovative Medicine EMEA
We inform you that the privacy policy at the remote site can be different from J&J Innovative Medicine EMEA. Click continue to proceed.
You are now leaving J&J Innovative Medicine EMEA
We inform you that the privacy policy at the remote site can be different from J&J Innovative Medicine EMEA. Click continue to proceed.
Psoriasispatiënten Nederland (PN), Netherlands
You are now leaving J&J Innovative Medicine EMEA
We inform you that the privacy policy at the remote site can be different from J&J Innovative Medicine EMEA. Click continue to proceed.
You are now leaving J&J Innovative Medicine EMEA
We inform you that the privacy policy at the remote site can be different from J&J Innovative Medicine EMEA. Click continue to proceed.
APIAFCO associazione psoriasici italiani amici della Fondazione Corazza, Italy
You are now leaving J&J Innovative Medicine EMEA
We inform you that the privacy policy at the remote site can be different from J&J Innovative Medicine EMEA. Click continue to proceed.
You are now leaving J&J Innovative Medicine EMEA
We inform you that the privacy policy at the remote site can be different from J&J Innovative Medicine EMEA. Click continue to proceed.
Deutscher Psoriasis Bund (DPB), Germany
You are now leaving J&J Innovative Medicine EMEA
We inform you that the privacy policy at the remote site can be different from J&J Innovative Medicine EMEA. Click continue to proceed.
You are now leaving J&J Innovative Medicine EMEA
We inform you that the privacy policy at the remote site can be different from J&J Innovative Medicine EMEA. Click continue to proceed.
References
[1] Janssen. Immunology – Psoriasis. Available at:
https://www.janssen.com/emea/our-focus/immunology/psoriasis. Accessed January 2023.
[2] Michalek IM and Loring B. World Health Organization: Global report on psoriasis. Available at:
https://www.who.int/publications/i/item/9789241565189. Accessed January 2023.
[3] van Ee I, et al. Freedom from disease in psoriasis: a Delphi consensus definition by patients, nurses and physicians. J Eur Acad Dermatol Venereol. 2022:36(3):403–412.
[4] Grine L, et al. A Belgian consensus on the definition of a treat-to-target outcome set in psoriasis management. J Eur Acad Dermatol Venereol. 2020:34(4):676–684.
[5] Strober BE, et al. Clinical Goals and Barriers to Effective Psoriasis Care. Dermatol Ther (Heidelb). 2019:9(1):5–18.
CP-459038
September 2024